Acute adverse events of hypofractionated whole-breast radiotherapy with a simultaneous-integrated boost – Results from the randomized controlled HYPOSIB-trial (ARO 2013-05)

David Krug

doi:10.1016/j.ijrobp.2026.07.022

Acute adverse events of hypofractionated whole-breast radiotherapy with a simultaneous-integrated boost – Results from the randomized controlled HYPOSIB-trial (ARO 2013-05)

2026-07-31

0

OA

AI

D

David Krug *

R

Reinhard Vonthein

A

Andreas Schreiber

A

Alexander D. Boicev

J

Jörg Zimmer

D

Dorit Uhlemann

R

Reinhold Laubach

N

N. Weidner

S

Stefan Dinges

M

Matthias Hipp

M

Marciana-Nona Duma

E

E Weinstrauch

J

Juliane Hörner-Rieber

A

Achim Rody

N

Nicolai Maass

J

Jörg Barkhausen

C

Christoph Röcken

D

Denise Olbrich

A

Alicia Droste

H

Hanna C.B. Grube

DOI：10.1016/j.ijrobp.2026.07.022

Original

Original request for help

Save

Abstract

En 中文

Moderate hypofractionation (HF) is standard of care for adjuvant whole-breast irradiation after breast-conserving surgery (BCS). While boost irradiation has traditionally been administered sequentially (seq) after whole-breast irradiation, a growing amount of data suggests that delivery of a simultaneous integrated boost (SIB) may be equally effective and tolerable.

Acute adverse events of hypofractionated whole-breast radiotherapy with a simultaneous-integrated boost – Results from the randomized controlled HYPOSIB-trial (ARO 2013-05)

Abstract

Journal

Organization

Cited Papers

Citing Papers